Tracer library / [177Lu]Lu-DOTA-MI-exendin-4

[177Lu]Lu-DOTA-MI-exendin-4

Also written as [Lu-177]Lu-DOTA-MI-exendin-4

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Pancreatic beta-cell imaging Pan-cancer / multiple tumour types Dosimetry and biodistribution studies Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated exendin-4 peptide analogue (GLP-1 receptor-targeting peptide) with Met-Ile cleavable linker
Target / mechanism: Targets the glucagon-like peptide-1 receptor (GLP-1R) PMID 37265006
Clinical application: Radionuclide therapy for GLP-1R-expressing tumours (e.g., insulinoma), aiming to reduce renal retention compared to standard DOTA-exendin-4 PMID 37265006
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	>90%	DOTA-MI-exendin-4 piCHEM, Raaba-Grambach, Austria	37265006 2023 Mol Pharm DOTA-exendin-4 and DOTA-MI-exendin-4 were labeled with 177Lu by incubating

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: piCHEM
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-MI-exendin-4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37265006. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37265006: 'Lys40[Mep((S-)DOTA-Met-Ile-Mal-)]exendin-4 (referred to as DOTA-MI-exendin-4)'.